Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying ...

Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of ...

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

The obesity drug developer has declared a new proposal from Novo “superior” to Pfizer’s original bid as well as an updated ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...